Repercussão cardiovascular, com e sem álcool, do carbonato de lodenafila, um novo inibidor da PDE5

FUNDAMENTO: A disfunção erétil afeta um grande número de homens no mundo e os inibidores de PDE 5 (iPDE5) estão entre os principais métodos de tratamento desses pacientes. O consumo social de álcool e o ato sexual apresentam uma relação considerável. Portanto, a associação entre álcool e iPDE5 pode ocorrer. O carbonato de lodenafila é um novo iPDE5 desenvolvido por uma empresa brasileira. OBJETIVO: Avaliar a repercussão cardiovascular do carbonato de lodenafila, associado ou não ao álcool, assim como as alterações na farmacocinética que esta associação possa determinar. MÉTODOS: Estudo realizado com 15 voluntários sadios que receberam em momentos diferentes o carbonato de lodenafila (CL) na dose de 160 mg em jejum, CL (160 mg) com álcool, ou somente placebo. Esses pacientes foram monitorados por 24 horas, sendo avaliado o quadro clínico, a pressão arterial (PA), a frequência cardíaca (FC), o intervalo QT e também os dados de farmacocinética. RESULTADOS: O carbonato de lodenafila, isoladamente ou associado com álcool, não determinou alterações clínicas significativas na PA ou FC, embora tenha ocorrido diminuição da PA estatisticamente significativa após 4 horas, nos voluntários que receberam medicamento e álcool, assim como um aumento da FC após 6 horas nos pacientes que receberam o CL. A análise do intervalo QT corrigido não mostrou alteração significativa. O álcool aumentou a biodisponibilidade do medicamento em 74%. Houve somente 2 queixas de cefaleia leve, possivelmente associada ao medicamento. CONCLUSÃO: O carbonato de lodenafila, mesmo associado ao álcool, não determinou repercussões clínicas importantes na PA, FC, ou alterações no intervalo QTc; a ingestão com álcool, por sua vez, aumentou significativamente sua biodisponibilidade.

Estatinas nas síndromes coronarianas agudas

As estatinas são o principal recurso disponível para redução do LDL-colesterol. Seu uso contínuo reduz a morbidade e a mortalidade cardiovascular decorrente da doença aterosclerótica. A administração das estatinas demonstrou ser efetiva em estudos clínicos de prevenção primária e secundária em pacientes de baixo e alto risco. O mecanismo presumido de benefício da terapia hipolipemiante na prevenção das complicações da doença aterosclerótica age na redução da deposição de lipoproteínas aterogênicas em áreas vulneráveis da vasculatura. Estudos experimentais com estatinas demonstraram grande variedade de outros efeitos que poderiam estender o benefício clínico além da modificação do perfil lipídico por si só. A terapia com estatinas altera beneficamente componentes importantes do processo aterotrombótico: inflamação, oxidação, coagulação, parâmetros fibrinolíticos, função endotelial, vasorreatividade e função plaquetária. A demonstração dos efeitos não dependentes da redução do colesterol ou pleiotrópicos das estatinas fornece a base teórica para seu possível papel como terapia adjunta das síndromes coronarianas agudas. Análises retrospectivas de uma variedade de estudos indicam potencial benefício das estatinas durante os eventos coronarianos agudos. Estudos clínicos recentes têm abordado essa importante questão em ensaios prospectivos controlados, demonstrando fortes evidências a favor da administração das estatinas como terapia adjunta nas síndromes coronarianas agudas.

Sons de Korotkoff: o improvável também ocorre

Poucas descobertas tiveram um impacto tão grande e tamanha relevância para a Medicina clínica como a medição não-invasiva da pressão arterial diastólica. Vários fisiologistas e clínicos talentosos estavam, sem sucesso, em busca de um método não-invasivo para determinar a pressão diastólica. No entanto, a quantificação da pressão arterial diastólica não foi conseguida por qualquer um desses pesquisadores clínicos ou fisiológicos, mas por uma figura improvável e inesperada: Nikolai Sergeevich Korotkoff (1874-1920), um jovem cirurgião do exército russo, trabalhando em condições precárias sob as dificuldades de diversas guerras. É fácil descartar o feito de Korotkoff como uma descoberta fortuita semelhante à de Alexander Fleming na descoberta da penicilina. No entanto, a recente teoria do cisne negro de Nassim N. Taleb pode servir para ilustrar sua descoberta de uma nova e, talvez, surpreendente, forma.

Fórmulas diretas de Ansheles

As "fórmulas diretas" do Professor Ansheles, cristalografista russo, são publicadas, sem dedução, na Cristalografia de BOLDYREV (1934), tradução para o espanhol de Candel Vila. No presente trabalho o autor deduz tais fórmulas, utilizando a projeção estereográfica.

Do funccionamento renal na febre amarella, na convalescença e após a cura

Graphico n. 1 - A. s. C., Reg. 169 A., 22 annos, branco, portuguez. Inicio com cephalalgia, mal estar e vomitos. Ao ser internado sentia grande abatimento, olhos injectados, ictericia bem nitida da esclerotica. Baço crescido. Dôr epigastrica. Bulhas cardiacas abafadas. Exame da urina: grande quantidade de albumina, cylindros granulosos, urobilina. Até o 13º dia continuou com grande adynamia. Até o 8º dia de molestia tinha cylindros na urina, persistindo depois traços de albumina. Graphico n. 2 - S. I. Reg. 829, 10 annos, branco, brasileiro. Adoeceu com dores musculares, fraqueza nos membros inferiores e peso na cabeça. Ao internar-se apresentava olhos brilhantes e injectados, e vaso dilatação peripherica. Baço augmentado. Durante 3 dias teve cylindros na urina e traços de albumina. Graphico n. 3 - I. D., Reg. 853, 14 annos, branco, russo. Inicio com cephalalgia, dores lombares e temperatura elevada. Ansiedade e dôres epigastricas. Vomitos de "borra de café" desde o 2º dia de molestia. Grande prostração, olhos brilhantes, sub-ictericia. Exame da urina, ao entrar: Grande quantidade de albumina, cylindros granulosos e epitheliaes e cellulas renaes. O estado do doente aggravou-se até o 7º dia de molestia, tendo dias de delirio. A ictericia augmentou progressivamente. Os signaes urinarios melhoraram depois do 16º dia. Graphico n. 4 - F. W., Reg. 165 A., 12 annos, branco, hungaro. Cephalalgia, fortes dores lombares, mau estar, vomitos e oppresão epigastrica. Grande prostração, rubor da face, vaso-dilatação peripherica. Face vultuosa. Depois de internado teve vomitos pretos. Os cylindros desappareceram depois do 8º dia e a albumina no 10º. Graphico n. 5 - A. H. M., 824, 22 annos, brancos, portuguez. Adoeceu com cephalalgia, dores lombares, calafrio e elevação thermica. Face vultuosa, olhos injectados. Albumina e cylindros na urina por muitos dias. Ictericia desde o 4º dia. Graphico n. 6 - Y. P., Reg. 824, 15 annos, branca, brasileira. Calafrios e elevação thermica. Cephalalgia e grande mal estar. Vomitos de "borra de café" desde o 4º dia. Nos primeiros dias o symptomas se aggravaram. Cylindruria até o 6º dia de molestia, restando traços de albumina. Graphico n. 7 - M. M., Reg. 829, 28 annos, branco, portuguez. Inicio com calafrios, febre, cephalalgia e dores lombares. Ao internar-se apresentava grande prostração, ruboe da face, olhos brilhantes e injectados. Lingua humida com muita saburra. A urina revelou grande quantidade de albumina e cylindros granulosos. Os signaes renaes duraram até o 16º dia. Não teve vomitos. Icterica intensa. Graphico n. 8 - A. S. S., Reg. 868, 18 annos, pardo, brasileiro. Internado em estado de confusão mental. Adynamia com grande apathia. Mucosas labiaes sangrando à pressão. Leve ictericia. Pequeno edema das palpebras. Baço palpavel. Oliguria. Grande quantidade de albumina e abundancia de cylindros granulosos e epitheliaes e cellulas renaes. Sómente depois de 10º dia de hospitalização foi que as melhoras se accentuaram e nesse dia desappareceram os cylindros. Traços de albumina. Graphico n. 9 - A. A. F., Reg. 821, 19 annos, branco, portuguez. Cephalalgia, rachialgia, adynamia. Face vultuosa. Suffusões sanguineas nos labios. As mucosas do nariz, gengivas e labios sangraram por muitos dias. Urina: grande quantidade de albumina, cylindros granulosos e epitheliaes e cellulas renaes, tendo este signaes desapparecido depois de 10º dia. Icterica muito accentuada.

A new murine model of persistent lung eosinophilic inflammation

We summarize here the main characteristics of a novel model of pulmonary hypersensitivity. Mice were immunized with a subcutaneous implant of a fragment of heat solidified chicken egg white and 14 days later challenged with ovalbumin given either by aerosol or by intratracheal instillation. This procedure induces a persistent eosinophilic lung inflammation, a marked bone marrow eosinophilia, and Th2-type isotypic profile with histopathological findings that resemble human asthma. Further, this model is simple to perform, reproducible in different strains of mice, does not require adjuvants nor multiple boosters. Based on these characteristics we propose it as a suitable murine model of allergic eosinophilic lung inflammation.

Prostaglandin A1 Inhibits Replication of Classical Swine Fever Virus

Prostaglandins (Pgs) have been shown to inhibit the replication of several DNA and RNA viruses. Here we report the effect of prostaglandin (PgA1) on the multiplication of a positive strand RNA virus, Classical Swine Fever Virus (CSFV) in PK15 cells. PgA1 was found to inhibit the multiplication of CSFV. At a concentration of 5 µg/ml, which was nontoxic to the cells, PgA1 inhibitis virus production in 99%. In PgA1 treated cells the size and number of characteristic Classical Swine Fever focus decreased in amount.

Nitric oxide paradox in asthma

Asthma results from allergen-driven intrapulmonary Th2 response, and is characterized by intermittent airway obstruction, airway hyperreactivity (AHR), and airway inflammation. Accumulating evidence indicates that inflammatory diseases of the respiratory tract are commonly associated with elevated production of nitric oxide (NO). It has been shown that exhaled NO may be derived from constitutive NO synthase (NOS) such as endothelial (NOS 3) and neural (NOS 1) in normal airways, while increased levels of NO in asthma appear to be derived from inducible NOS2 expressed in the inflamed airways. Nevertheless, the functional role of NO and NOS isoforms in the regulation of AHR and airway inflammation in human or experimental models of asthma is still highly controversial. In the present commentary we will discuss the role of lipopolysaccharides contamination of allergens as key element in the controversy related to the regulation of NOS2 activity in experimental asthma.

First isolation of microorganisms from the gut diverticulum of Aedes aegypti (Diptera: Culicidae): new perspectives for an insect-bacteria association

We show for the first time that the ventral diverticulum of the mosquito gut (impermeable sugar storage organ) harbors microorganisms. The gut diverticulum from newly emerged and non-fed Aedes aegypti was dissected under aseptic conditions, homogenized and plated on BHI medium. Microbial isolates were identified by sequencing of 16S rDNA for bacteria and 28S rDNA for yeast. A direct DNA extraction from Ae. aegypti gut diverticulum was also performed. The bacterial isolates were: Bacillus sp., Bacillus subtilis and Serratia sp. The latter was the predominant bacteria found in our isolations. The yeast species identified was Pichia caribbica.

Comparison of serological responses in two different populations with pulmonary tuberculosis

Observational studies on the humoural immune responses of the Warao indigenous people from Delta Amacuro, an isolated area, were compared with urban residents of the Venezuelan capital. Mycobacterium tuberculosis-specific reactivities (IgM, IgE, sIgA, IgG and IgG subclasses) were measured by ELISA using PPD and 38-kDa M. tuberculosis antigens. A total of 294 individuals were studied, 162 Warao (indigenous people) and 132 Creole (non-indigenous people). The patient group consisted of 87 Warao patients and 58 Creole patients, while the control group consisted of 75 Warao controls and 74 Creole controls. Combinations among the isotypes studied were performed. The findings showed that for the Warao people, sensitivity to the combination including anti-PPD IgG and IgE was 92.0%, while for the Creole people, sensitivity to the combination including anti-PPD IgG but more so anti-PPD IgG1 and IgG2 was 90.0%. Simple tests were able to show higher specificities, which were population-specific; specificities were anti-PPD IgG3, 100.0% and anti-PPD IgM, 97.4% for the Warao and Creole peoples, respectively. In conclusion, while simple tests reached high specificity, the multi-isotype tests improved sensitivity; the latter shows this approach may be useful in diagnostic testing.

In vitro and in vivo experimental models for drug screening and development for Chagas disease

Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Although the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been assayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.

Soluble inflammatory markers as predictors of virological response in patients with chronic hepatitis C virus infection treated with interferon-α plus ribavirin

The host immune response plays an important role in viral clearance in patients who are chronically infected with hepatitis C virus (HCV) and are treated with interferon and ribavirin. Activation of the immune system involves the release of pro and anti-inflammatory molecules that can be measured in plasma samples. The present study aimed to evaluate the association between pretreatment plasma levels of chemokines and soluble tumor necrosis factor receptors (sTNF-R) and the virological response in treated patients with chronic hepatitis C infection. Forty-one chronically-infected HCV patients that were being treated with interferon-α (IFN-α) plus ribavirin were included in the study. Socio-demographic, clinical and laboratory data were collected and pretreatment plasma levels of chemokine CCL2, CCL3, CCL11, CCL24, chemokine CXCL9, CXCL10, sTNF-R1 and sTNF-R2 were measured. The virological response was assessed at treatment week 12, at the end of treatment and 24 weeks after treatment. Pretreatment CXCL10 levels were significantly higher in patients without an early virological response (EVR) or sustained virological response (SVR) compared to responders [512.9 pg/mL vs. 179.1 pg/mL (p = 0.011) and 289.9 pg/mL vs. 142.7 pg/mL (p = 0.045), respectively]. The accuracy of CXCL10 as a predictor of the absence of EVR and SVR was 0.79 [confidence interval (CI) 95%: 0.59-0.99] and 0.69 (CI 95%: 0.51-0.87), respectively. Pretreatment plasma levels of the other soluble inflammatory markers evaluated were not associated with a treatment response. Pretreatment CXCL10 levels were predictive of both EVR and SVR to IFN-α and ribavirin and may be useful in the evaluation of candidates for therapy.

Ionic imbalance and lack of effect of adjuvant treatment with methylene blue in the hamster model of leptospirosis

Leptospirosis in humans usually involves hypokalaemia and hypomagnesaemia and the putative mechanism underlying such ionic imbalances may be related to nitric oxide (NO) production. We previously demonstrated the correlation between serum levels of NO and the severity of renal disease in patients with severe leptospirosis. Methylene blue inhibits soluble guanylyl cyclase (downstream of the action of any NO synthase isoforms) and was recently reported to have beneficial effects on clinical and experimental sepsis. We investigated the occurrence of serum ionic changes in experimental leptospirosis at various time points (4, 8, 16 and 28 days) in a hamster model. We also determined the effect of methylene blue treatment when administered as an adjuvant therapy, combined with late initiation of standard antibiotic (ampicillin) treatment. Hypokalaemia was not reproduced in this model: all of the groups developed increased levels of serum potassium (K). Furthermore, hypermagnesaemia, rather than magnesium (Mg) depletion, was observed in this hamster model of acute infection. These findings may be associated with an accelerated progression to acute renal failure. Adjuvant treatment with methylene blue had no effect on survival or serum Mg and K levels during acute-phase leptospirosis in hamsters.

Serial measurement of the circulating levels of tumour necrosis factor and its soluble receptors 1 and 2 for monitoring leprosy patients during multidrug treatment

Leprosy is an infectious and contagious spectral disease accompanied by a series of immunological events triggered by the host response to the aetiologic agent, Mycobacterium leprae . The induction and maintenance of the immune/inflammatory response in leprosy are linked to multiple cell interactions and soluble factors, primarily through the action of cytokines. The purpose of the present study was to evaluate the serum levels of tumour necrosis factor (TNF)-α and its soluble receptors (sTNF-R1 and sTNF-R2) in leprosy patients at different stages of multidrug treatment (MDT) in comparison with non-infected individuals and to determine their role as putative biomarkers of the severity of leprosy or the treatment response. ELISA was used to measure the levels of these molecules in 30 healthy controls and 37 leprosy patients at the time of diagnosis and during and after MDT. Our results showed increases in the serum levels of TNF-α and sTNF-R2 in infected individuals in comparison with controls. The levels of TNF-α, but not sTNF-R2, decreased with treatment. The current results corroborate previous reports of elevated serum levels of TNF-α in leprosy and suggest a role for sTNF-R2 in the control of this cytokine during MDT.